Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Panthera Resources | London | Basic Materials | Metals & Mining | 125.3% | £41.04M | -7.2x | -0.68 | GBX 16.90 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
OncoCyte | London | Healthcare | Biotechnology & Medical Research | 89.8% | £73.86M | -0.7x | 0.07 | GBX 273.28 | 18.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
REC Silicon | London | Basic Materials | Chemicals | 56.1% | £63.92M | -0.5x | 0 | GBX 15.25 | 20.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verastem | London | Healthcare | Biotechnology & Medical Research | 42.2% | £289.92M | -1.6x | -0.39 | GBX 593.11 | 8.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
New Wave Group | London | Consumer Cyclicals | Textiles & Apparel | 10.2% | £1.14B | 15.9x | -1.45 | GBX 875.74 | 8.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Corbus Pharmaceuticals Holdings | London | Healthcare | Biotechnology & Medical Research | -19.5% | £74.21M | -1.8x | -0.04 | GBX 598.36 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Wolfspeed | London | Technology | Semiconductors & Semiconductor Equipment | -46.2% | £381.93M | -0.8x | 0.02 | GBX 243.25 | 4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |